Record Quarterly Revenues of $708.0 Million, a 26% Increase from a Year Ago Quarterly Adjusted EBITDA (non-GAAP) Increased 39% from Prior Year Record Total Backlog and Awards of $3.1 Billion, 29% ...
Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback